文献速递淋巴瘤造血干细胞移植与细胞治疗

早期淋巴细胞采集用于抗CD19 CAR-T制备可改善复发/难治性弥漫大B细胞淋巴瘤患者的T细胞适合度

Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.
PubMed 文献 · Br J Haematol · 2023-04-18

这项前瞻性研究比较了首次复发时早期淋巴细胞采集(早期组,n=22)与标准采集(第二次复发及以后,标准组,n=23)对CD19-CAR-T输注的复发/难治性弥漫大B细胞淋巴瘤患者临床结局的影响;早期组初始T细胞比例和体外T细胞功能增加、耗竭特征降低,但未转化为显著改善的临床结局,观察到总生存和无进展生存有改善趋势。

要点

  • 早期组(n=22)初始T细胞比例和体外T细胞功能增加,耗竭特征低于标准组(n=23)。
  • T细胞表型和功能改善未转化为显著改善的临床结局。
  • 观察到总生存和无进展生存有改善趋势。

核心结论

  • 早期淋巴细胞采集可最大化挽救治疗的潜力,且不损害CAR-T细胞质量。
  • 淋巴细胞采集产物中T细胞表型和功能的改善未转化为显著改善的临床结局,但观察到总生存和无进展生存有改善趋势。

研究设计与样本

  • 前瞻性研究,比较首次复发时早期淋巴细胞采集(早期组,n=22)与第二次复发及以后标准采集(标准组,n=23)对CD19-CAR-T输注的复发/难治性弥漫大B细胞淋巴瘤患者临床结局的影响。

主要发现

  • 早期组初始T细胞比例增加,体外T细胞功能增加。
  • 早期组T细胞耗竭特征低于标准组采集的T细胞。
  • T细胞表型和功能改善未转化为显著改善的临床结局。
  • 观察到总生存和无进展生存有改善趋势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chimeric antigen receptor (CAR) T cells targeted to the CD19 B-cell antigen form an approved treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). However, since this therapy is administered after multiple lines of treatment and exposure to lymphotoxic agents, there is an urgent need to optimize this modality of treatment. METHODS: To circumvent the difficulties of harvesting adequate and optimal T cells from DLBCL patients and improve CART therapy, we suggest an earlier lymphopheresis (i.e. at first relapse, before salvage treatment). We conducted a prospective study and evaluated the potential benefit of an earlier lymphopheresis (early group, n = 22) on the clinical outcome of CD19-CART infused DLBCL patients, in comparison with standard lymphopheresis (i.e. at second relapse and beyond; standard group, n = 23). RESULTS: An increased percentage of naïve T cells and increased in vitro T-cell functionality were observed in the early group. Additionally, these cells exhibit a lower exhaustion profile than T cells collected in the standard group. CONCLUSION: While improved T-cell phenotype and function in the lymphopheresis product did not translate into significantly improved clinical outcomes, a trend towards better overall survival (OS) and progression-free survival (PFS) was observed. Early lymphopheresis maximizes the potential of salvage therapies, without compromising CAR T-cell quality.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Dubnikov Sharon T, Assayag M, Avni B, et al. Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma. Br J Haematol. 2023. PMID: 37070396. doi:10.1111/bjh.18816

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。